In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
Nearly 70% of adults with moderate to severe atopic dermatitis treated with telikibart reached EASI-75 at Week 16, roughly triple the placebo rate, according to phase 3 results presented as a late-breaking abstract at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria. By Week 52, more than 9 in 10 patients on continuous or crossover therapy achieved this threshold.¹
Telikibart, also known as GR1802, is a fully human monoclonal antibody against the interleukin 4 receptor alpha (IL-4Rα) subunit, blocking both IL-4 and IL-13 signaling. Its Fc region carries 3 engineered mutations designed to eliminate antibody-dependent cell-mediated cytotoxicity, a modification the investigators linked to a favorable safety profile.¹
The trial was conducted across dozens of dermatology centers in China, with authors led by Shangshang Wang of Huashan Hospital, Fudan University, in Shanghai. A prior phase 2 study had shown early efficacy signals in this population.¹
The randomized, placebo-controlled trial (NCT06216392) enrolled 450 adults between January 2024 and August 2025, assigning them 2:1 to telikibart (n = 299) or placebo (n = 151). Patients received a 600 mg loading dose followed by 300 mg every 2 weeks during a 16-week induction period.¹˒²
All participants then received telikibart 300 mg every 2 weeks through Week 52, with placebo recipients given a 600 mg loading dose at crossover.¹
Coprimary end points at the 16 week mark were EASI-75 and Investigator's Global Assessment (IGA) 0/1 with at least a 2-point improvement from baseline.¹
At Week 16, 69.6% of patients receiving telikibart achieved EASI-75 compared with 22.5% receiving placebo (difference, 47.1%; 95% CI, 38.62-55.50; P < .0001). IGA 0/1 response reached 33.1% versus 6.6% (difference, 26.5%; 95% CI, 19.86-33.15; P < .0001).¹
Telikibart also outperformed placebo on EASI-90, a reduction of at least 4 points in weekly average Peak Pruritus Numerical Rating Scale (PP-NRS) score, and least squares mean improvement in Dermatology Life Quality Index (all P < .0001).¹
Responses deepened during maintenance. At the 52-week mark, EASI-75 rates were 94.3% among patients treated with telikibart throughout and 95.9% among those switched from placebo. IGA 0/1 rates reached 65.4% and 58.5%, and itch improvement of at least 4 points was achieved by 76.0% and 76.7%, respectively.¹
Prespecified subgroup analyses showed higher Week 16 EASI-75 rates with telikibart versus placebo in every subgroup assessed (all P < .01). This included patients previously treated with other IL-4Rα inhibitors and those with prior immunosuppressant exposure. The investigators cited these findings as further support for the consistency of telikibart's treatment effect.¹
During the 16-week double-blind period, treatment-emergent adverse events occurred in 64.5% of the telikibart group and 57.6% of the placebo group. Across the full study, 82.2% of patients receiving at least 1 dose of telikibart experienced an adverse event, most rated grade 1 or 2 by Common Terminology Criteria for Adverse Events version 5.0.¹
The abstract did not identify which adverse events were most common or report rates of serious events or discontinuations.
Week 52 results reflect open-label treatment in both groups, so they were not compared statistically, and the abstract did not describe how missing data were handled or how many patients completed the study. Because the trial enrolled only adults at centers in China, findings may not extend to adolescents or other populations.
Editor’s note: This summary has been edited for grammar and clarity using artificial intelligence tools.
References
